Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH: Perindopril Arginine/Amlodipine Besylate in Essential Hypertension
NCT01556997Phase 3Completed
- Sponsor
- Symplmed Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perindopril and amlodipine in essential hypertension (3 arms), sponsored by Symplmed Pharmaceuticals. Primary endpoint: Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure at Day 42. Started Feb 2012; status: completed.
02
Drugs
perindoprilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01556997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556997.